CM336-SOC for Dynamically High-Risk Multiple Myeloma Study
NCT07648459
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
46
Enrollment
OTHER
Sponsor class
Conditions
Multiple Myeloma
Interventions
DRUG:
anti-BCMA/CD3 bispecific antibody
Sponsor
Institute of Hematology & Blood Diseases Hospital, China